Delfi Diagnostics Funding: $400M Raised, Series B (2022)
Delfi Diagnostics is a Biotech company based in San Francisco, CA. It has raised $400M in total funding. Latest round: Series B.
Delfi Diagnostics funding overview
Delfi Diagnostics is a Biotech company based in San Francisco, CA. Delfi Diagnostics has raised $400M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series B announced in July 2022. The round record for Delfi Diagnostics runs through 2022; nothing later has been disclosed. Investors on record include DFJ Growth, Eli Lilly and Company, Point72, Brown Advisory, Foresite Capital, Menlo Ventures and 6 others. 12 distinct backers are named across the disclosed rounds.
Delfi Diagnostics at a glance
Total raised
$400M
Latest round
Series B
Latest round date
July 2022
Industry
Biotech
Headquarters
San Francisco, CA
Notable investors
DFJ Growth, Eli Lilly and Company, Point72, Brown Advisory, Foresite Capital, Menlo Ventures, OrbiMed, T. Rowe Price
Frequently asked about Delfi Diagnostics funding
How much has Delfi Diagnostics raised?
Delfi Diagnostics has raised $400M in total disclosed funding across the rounds on record.
Who has invested in Delfi Diagnostics?
DFJ Growth, Eli Lilly and Company, Point72, Brown Advisory, Foresite Capital, Menlo Ventures are named among the investors backing Delfi Diagnostics.
What was the latest Delfi Diagnostics funding round?
The most recent disclosed round is a Series B, announced in July 2022.
Where is Delfi Diagnostics based?
Delfi Diagnostics is based in San Francisco, CA.
What sector does Delfi Diagnostics operate in?
Delfi Diagnostics is tracked under Biotech from San Francisco, CA, with $400M in disclosed funding.
When did Delfi Diagnostics last raise?
The last disclosed Delfi Diagnostics round closed in July 2022 at Series B.
Totals shown for Delfi Diagnostics aggregate every disclosed round on file. To see how that compares, browse the Biotech companies in San Francisco and the investors behind them below.
